EA201991313A1 - PRESERVATION OF THE IMMUNE RESPONSE DURING CHEMOTHERAPEUTIC SCHEMES - Google Patents
PRESERVATION OF THE IMMUNE RESPONSE DURING CHEMOTHERAPEUTIC SCHEMESInfo
- Publication number
- EA201991313A1 EA201991313A1 EA201991313A EA201991313A EA201991313A1 EA 201991313 A1 EA201991313 A1 EA 201991313A1 EA 201991313 A EA201991313 A EA 201991313A EA 201991313 A EA201991313 A EA 201991313A EA 201991313 A1 EA201991313 A1 EA 201991313A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- short
- preservation
- schemes
- immune response
- response during
- Prior art date
Links
Abstract
Добавление селективного, быстродействующего, характеризующегося коротким периодом полужизни ингибитора CDK 4/6 согласно очень специфической схеме дозирования к комбинации химиотерапевтического средства с ингибитором контрольных точек обеспечивает превосходные результаты в лечении опухоли или рака. Неожиданное открытие заключается в том, что короткое импульсное специально рассчитанное по времени введение селективного, быстродействующего, характеризующегося коротким периодом полужизни ингибитора CDK 4/6 во время назначения химиотерапевтической части в составе тройной комплексной терапии оказывает глубокое воздействие на иммунные клетки в раковом микроокружении.Adding a selective, fast-acting, short-half-life CDK 4/6 inhibitor according to a very specific dosing schedule to the combination of a chemotherapeutic agent with a control point inhibitor provides excellent results in treating a tumor or cancer. An unexpected discovery is that a short, pulsed, specially timed administration of a selective, fast-acting, short-half-life CDK 4/6 inhibitor during the administration of the chemotherapeutic part of the triple complex therapy has a profound effect on immune cells in the cancerous microenvironment.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762479605P | 2017-03-31 | 2017-03-31 | |
PCT/US2017/064775 WO2018106729A1 (en) | 2016-12-05 | 2017-12-05 | Preservation of immune response during chemotherapy regimens |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201991313A1 true EA201991313A1 (en) | 2019-10-31 |
Family
ID=68319040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201991313A EA201991313A1 (en) | 2017-03-31 | 2017-12-05 | PRESERVATION OF THE IMMUNE RESPONSE DURING CHEMOTHERAPEUTIC SCHEMES |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA201991313A1 (en) |
-
2017
- 2017-12-05 EA EA201991313A patent/EA201991313A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023006991A (en) | Preservation of immune response during chemotherapy regimens. | |
WO2017176628A8 (en) | Methods for solid tumor treatment | |
MX2021002415A (en) | Genetically engineered hematopoietic stem cells and uses thereof. | |
PH12016500841A1 (en) | Combinations of checkpoint inhibitors and therapeutics to treat cancer | |
PH12020550400A1 (en) | Combination therapies and uses thereof | |
MX2019013755A (en) | Combination therapies for treating cancer. | |
AU2018341571A8 (en) | Therapeutic methods relating to HSP90 inhibitors | |
MA40437A (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
MX2021012977A (en) | Treatment of cancer with tg02. | |
MX2017015896A (en) | Anticancer agent. | |
MX2021009899A (en) | Administration and dosage of diaminophenothiazines. | |
EA201591924A1 (en) | METHODS OF TREATING MALIGNANT TUMOR USING COMBINED THERAPY WITH COFFEE Q10 | |
EA201790913A1 (en) | TREATMENT OF DISEASES ASSOCIATED WITH THE ACTIVATION OF STARZED LIVER CELLS WITH THE APPLICATION OF TYPES OF THERAPY REDUCING AMMONIA | |
NZ754865A (en) | Combination therapy for the treatment of cancer | |
BR112018013063A2 (en) | bromodomain inhibitor and extra-terminal protein combination | |
MX2019003546A (en) | Optimized oncolytic viruses and uses thereof. | |
EA202191556A1 (en) | COMBINED THERAPY WITH RADIO IMMUNOCONJUGATES AND CONTROL POINT INHIBITORS | |
MX2020001727A (en) | Combination therapy. | |
PH12021551036A1 (en) | Anti-liv1 immune cell cancer therapy | |
MX2019015676A (en) | Use of isovalerylspiramycin i, ii and/or iii in preparation of drug for treating and/or preventing tumour, and drug. | |
MX2021000828A (en) | Tumor-selective combination therapy. | |
MX2021001606A (en) | Treatment of b cell malignancies. | |
MX2019007727A (en) | Reducing damage from radiation therapy and increasing cancer kill rates by interweaving of low and high dose sessions. | |
MX2015009260A (en) | Selective glycosidase regimen for immune programming and treatment of cancer. | |
EA201991313A1 (en) | PRESERVATION OF THE IMMUNE RESPONSE DURING CHEMOTHERAPEUTIC SCHEMES |